CLDX at a glance
Celldex Therapeutics, Inc. (CLDX, SEC CIK 744218) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as June 29, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Celldex Therapeutics, Inc. (CLDX) reported revenue of $1.5 million (down 78.0% from FY2024) and a net loss of $258.8 million. Diluted EPS was -$3.90.
- As of September 30, 2026, 24 institutional investment managers tracked by SignalX reported holding Celldex Therapeutics, Inc. (CLDX) shares worth $843.9 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $1.5M
- −78.0% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 24 funds
- $843.9M · −3 vs prior quarter
- Latest 8-K
- Nov 5, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: Development of therapeutic antibodies targeting mast cell biology for severe inflammatory and autoimmune diseases
- New emphasis on bispecific antibody platform, highlighted by CDX-622 targeting TSLP and SCF with Phase 1 studies initiated in 2024-2026
- Strategic shift toward building a fully integrated, commercial-stage biopharma company with potential for retaining full economic rights or forming partnerships
- Phase 3 enrollment completed for Barzolvolimab in Chronic Spontaneous Urticaria; topline data expected Q4 2026
- Notable sustained efficacy: over 40% of CSU patients maintained complete response at 76 weeks post-dosing with Barzolvolimab
Risk Factors
- FDA regulatory delays from recent 43-day government shutdown Oct-Nov 2025 impacting review timelines
- Global supply chain disruptions threatening clinical trial material supplies and contract manufacturing capacity
- Clinical trial enrollment challenges due to patient recruitment difficulties risking costly delays or trial cancellations
- Market competition risk from other monoclonal antibody developers with more advanced or approved therapies
- $52.5M milestone payment under Kolltan merger may require dilutive stock issuance or additional debt funding
Management Discussion & Analysis
- R&D expenses $245.1M in 2025 vs $163.6M in 2024 and $118.0M in 2023, driven by barzolvolimab program ($198.3M in 2025)
- Barzolvolimab program best performing segment with $198.3M R&D spend; CDX-622 at $19.0M; no revenue or profit data provided
- Management expects topline Phase 3 data for CSU indication in Q4 2026; key risk: lengthy, costly clinical trials, uncertain regulatory approvals, and capital needs
AI summary of the CLDX 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material changes identified in the provided Risk Factors section, which contains no substantive risk-factor disclosure
- Liquidity risk: $650.3 million in cash, equivalents and marketable securities against $188.0 million operating cash burn
- Financing risk: future $52.5 million milestone payment may require cash, stock or a combination
- Regulatory risk: barzolvolimab remains subject to potential clinical-trial failure or regulatory approval delays
- Marketable-securities risk: unrealized-loss positions increased to $576.5 million from $19.4 million
Management Discussion & Analysis
- Quarterly revenue $0, unchanged YoY from $0
- Operating margin not meaningful, operating loss $82.3M vs $73.6M YoY
- Barzolvolimab strongest program, Phase 3 CSU complete response up to 54.0% at Week 24
- Cash, equivalents and marketable securities $650.3M; operating cash use $188.0M
- BLA submission anticipated in 2027; higher barzolvolimab development costs expected near term
AI summary of the CLDX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Celldex announced third-quarter 2026 financial results on November 5, 2026
- Detailed financial figures and operating commentary are contained in Exhibit 99.1, the accompanying press release
Item EX-99.1: Item EX-99.1
- Phase 3 EMBARQ-CSU1 and CSU2 met primary and key secondary endpoints, supporting barzolvolimab’s potential in chronic spontaneous urticaria
- BLA submission for barzolvolimab in CSU anticipated in 2027, creating a defined regulatory catalyst
Item 8.01: Other Events
- Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 results announced for barzolvolimab in chronic spontaneous urticaria
- Clinical readout is material to barzolvolimab’s regulatory path and Celldex’s commercial prospects
Item EX-99.1: Item EX-99.1
- Phase 3 EMBARQ-CSU1 and CSU2 met primary and all key secondary endpoints, materially reducing barzolvolimab’s clinical risk
- Complete response at Week 24 reached 49.0%-54.0% versus 15.4%-17.6% for placebo, supporting competitive differentiation
Item EX-99.1: Item EX-99.1
- Cash and marketable securities $717.6M after $323.8M offering proceeds, funding planned operations through 2028
- Phase 3 CSU enrollment complete with 1,939 patients, topline data expected September/October 2026
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results announced by Celldex Therapeutics
- Full results, including financial metrics and management commentary, contained in Exhibit 99.1
AI summaries of CLDX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CLDX
Don't miss the next CLDX filing
- Alerts as it files. A push when CLDX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CLDX, by share count.
- Ask anything. An AI agent that reads every CLDX filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Brownlie Keith L | A | Jun 25, 2026 | 26,000 | - |
| PENNER HARRY JR | A | Jun 25, 2026 | 26,000 | - |
| Cohen Cheryl | A | Jun 25, 2026 | 26,000 | - |
| CONRAD HERBERT J | A | Jun 25, 2026 | 26,000 | - |
| MARINO JAMES J | A | Jun 25, 2026 | 26,000 | - |
| Torres Denice | A | Jun 25, 2026 | 26,000 | - |
| NEIL GARRY ARTHUR | A | Jun 25, 2026 | 26,000 | - |
| NEIL GARRY ARTHUR | A | Jun 25, 2026 | 26,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $7.0M | $1.5M |
| Operating Income | - | -$195.1M | -$287.4M |
| Net Income | -$141.4M | -$157.9M | -$258.8M |
| Op. Margin | - | -2778.9% | -18599.8% |
| Net Margin | - | -2248.8% | -16748.0% |
| Balance Sheet | |||
| Total Assets | $465.6M | $792.3M | $583.0M |
| Equity | - | $747.0M | $527.2M |
| ROE | - | -21.1% | -49.1% |
| Per Share | |||
| EPS | $-2.92 | $-2.45 | $-3.90 |
| Cash Flow | |||
| Operating CF | - | -$157.8M | -$210.9M |
| CapEx | $1.8M | $1.9M | $2.7M |
Source: XBRL data in Celldex Therapeutics, Inc. (CLDX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate CLDX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 24 | $843.9M |
| Q2 2026 | 27 | $1.15B |
| Q1 2026 | 26 | $745.9M |
| Q4 2025 | 23 | $680.5M |
| Q3 2025 | 23 | $642.2M |
| Q2 2025 | 23 | $529.8M |
| Q1 2025 | 19 | $303.5M |
| Q4 2024 | 17 | $367.1M |
- Morgan Stanley+398.8K (+202%)
- Bank of America Corp+263.4K (+43%)
- Two Sigma Investments+220.9K (+33%)
- Dimensional Fund Advisors+74.5K (+7%)
- AQR Capital Management+46.6K (+54%)
- Millennium Management−833.3K (-71%)
- State Street Corp−421.9K (-11%)
- Citigroup−367.8K (-91%)
- T. Rowe Price Group−299.3K (-6%)
- JPMorgan Chase & Co−95.0K (-60%)
- FMR LLC (Fidelity)−3.72M
- D.E. Shaw & Co−17.8K
- Allstate−7.8K
- Blackstone Group−6.4K
- Ameriprise Financial−5.6K
Source: 13F-HR filings on SEC EDGAR (aggregated from 182 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CLDX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Sep 22, 2026 | - | Analysis | - |
| SC 13G | Aug 14, 2026 | - | - | |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 8-K | Jul 15, 2026 | - | Analysis | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
Related Health Care companies
- TKNO · Alpha Teknova, Inc.In Vitro & In Vivo Diagnostic Substances
- IDXX · Idexx LaboratoriesIn Vitro & In Vivo Diagnostic Substances
- NTLA · Intellia Therapeutics, Inc.In Vitro & In Vivo Diagnostic Substances
- LNTH · Lantheus Holdings, Inc.In Vitro & In Vivo Diagnostic Substances
- MYGN · MYRIAD GENETICS INCIn Vitro & In Vivo Diagnostic Substances
- NEOG · NEOGEN CORPIn Vitro & In Vivo Diagnostic Substances
- QDEL · QuidelOrtho CorpIn Vitro & In Vivo Diagnostic Substances
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
CLDX SEC filings: frequently asked questions
Which institutions hold CLDX stock?
As of September 30, 2026, the largest Celldex Therapeutics, Inc. (CLDX) holders among the 13F filers tracked by SignalX were BlackRock ($225.2 million), T. Rowe Price Group ($142.1 million), State Street Corp ($112.7 million), Vanguard Capital Management LLC ($112.7 million), Goldman Sachs Group ($52.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was CLDX's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Celldex Therapeutics, Inc. (CLDX) reported revenue of $1.5 million (down 78.0% from FY2024) and a net loss of $258.8 million. Diluted EPS was -$3.90. The figures come from the XBRL data in the 10-K.
What are the main risks in CLDX's latest 10-K?
In the 10-K filed February 25, 2026, Celldex Therapeutics, Inc. (CLDX) flagged: FDA regulatory delays from recent 43-day government shutdown Oct-Nov 2025 impacting review timelines. Global supply chain disruptions threatening clinical trial material supplies and contract manufacturing capacity. (AI summary of the Risk Factors section.)
What did CLDX report in its latest 8-K?
Celldex Therapeutics, Inc. (CLDX) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Celldex announced third-quarter 2026 financial results on November 5, 2026.
What are the latest CLDX SEC filings?
Celldex Therapeutics, Inc. (CLDX) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on June 29, 2026.
What is CLDX's SEC CIK number?
Celldex Therapeutics, Inc. (CLDX)'s SEC Central Index Key (CIK) is 744218. EDGAR lists every CLDX filing under that number.
Ask anything about CLDX
The research agent reads CLDX's filings, financials, insider trades and 13F holders, then answers with sources.